Shin Nippon Biomedical Laboratories' consolidated ordinary profit for the first half rose 89.4% year on year to ¥3.08 billion. July–September profit was ¥1.64 billion, up 48.2% year on year.
Shin Nippon Biomedical Laboratories announced its earnings on 10 November 2026, reporting consolidated ordinary profit of ¥3.08 billion for the April–September period, up 89.4% year on year. The full-year plan is ¥6.0 billion, putting first-half progress against the plan at 51.4%.
Consolidated ordinary profit for July–September was ¥1.64 billion, up 48.2% year on year, while the operating margin on sales improved sharply from 4.7% to 10.7%.
Based on the full-year plan, ordinary profit for the October–March period is expected to fall to ¥2.91 billion in the second-half outlook, representing a decline from the same period a year earlier.